Related Experiment Videos
Treatment of acute cryptococcal disease
A Apisarnthanarak1, W G Powderly
1Division of Infectious Diseases Washington University School of Medicine St. Louis, Missouri 63110, USA.
Expert Opinion on Pharmacotherapy
|October 5, 2001
Summary
Treatment for cryptococcal disease has advanced significantly with amphotericin B, improving outcomes and reducing treatment duration. Current strategies focus on amphotericin B, with choices depending on disease site and immune status.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Cryptococcal disease treatment has evolved, with significant improvements in outcomes over the last 15-20 years.
- Amphotericin B, a polyene antifungal, has been central to successful cryptococcal disease management.
- Most research focuses on AIDS-associated cryptococcal disease, particularly cryptococcal meningitis.
Purpose of the Study:
- To review current therapeutic strategies for cryptococcal disease.
- To discuss the factors influencing treatment choices, including anatomical site and host immune status.
- To highlight advancements in managing acute cryptococcal disease.
Main Methods:
- Literature review of recent therapeutic strategies for cryptococcal disease.
- Analysis of treatment outcomes based on drug regimens and patient characteristics.
- Discussion of established and emerging treatment guidelines.
Main Results:
- Amphotericin B, often combined with flucytosine, is the recommended initial therapy for severe cryptococcal disease and meningitis.
- Alternative antifungal agents like azoles and other amphotericin B formulations are considered for specific situations.
- Treatment efficacy is influenced by the anatomical location of the infection and the patient's immune system.
Conclusions:
- Modern therapeutic strategies have markedly improved cryptococcal disease treatment outcomes.
- Treatment selection requires careful consideration of disease presentation and patient factors.
- Continued research and guideline updates are essential for optimal cryptococcal disease management.